27 results about "Dexmedetomidine" patented technology

This specification discloses a method for administering dexmedetomidine or a pharmaceutically acceptable salt thereof to human subjects. The disclosed method is particularly suitable for the treatment of agitation associated with neurodegenerative diseases and / or neuropsychiatric disorders or disorders (e.g., Alzheimer's disease).

To provide methods of providing sedation or analgesia to a pediatric patient.SOLUTION: The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More specifically, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during or after surgery.SELECTED DRAWING: Figure 1

The present disclosure relates to compositions, formulations, and associated methods for treating neurodegenerative diseases, wherein the compositions include an alpha-1 adrenergic agonist, such as midodrine, and an alpha-2A adrenergic agonist, such as dexmedetomidine. Upon administering to a human subject, the alpha-2A adrenergic agonist crosses the subject's blood-brain barrier thereby acting upon the subject's central nervous system, whereas the alpha-1 adrenergic agonist does not cross the subject's blood-brain barrier. The alpha-1 adrenergic agonist minimizes or eliminates the systemic vascular effects induced by the alpha-2A adrenergic agonist that causes the negative cerebral autoregulatory response, thereby enabling the alpha-2A adrenergic agonist to increase glymphatic flow in the subject's brain.

The present invention relates to methods of treating agitation using transdermal delivery patches containing dexmedetomidine.

This invention relates to pharmaceutical compositions, including compositions adapted for intranasal administration, comprising an active ingredient, including dexmedetomidine, pomalidomide, a selective phosphodiesterase type 4 inhibitor such as roflumilast, or combinations thereof, useful in the treatment of traumatic brain injury (TBI), including to prevent or reduce the neurological sequalae of TBI.

To provide a composition or the like for treating agitation or signs of agitation.SOLUTION: The present invention discloses a method of treating agitation or signs of agitation in a subject comprising sublingual administration of an effective amount of an alpha-2 adrenergic agent, more particularly dexmedetomidine or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative diseases and / or neuropsychiatric diseases. The present invention also discloses sublingual administration of an alpha-2 adrenergic agent, more specifically dexmedetomidine or a pharmaceutically acceptable salt thereof, at a dose that is effective to treat agitation or the symptoms of agitation but does not cause significant sedation in the subject.SELECTED DRAWING: Figure 1A

Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. In some embodiments, methods include hydrating the subject, such as by administering a hydration fluid composition to the subject. Methods according to certain embodiments may also include co-administering an opioid to the subject. Also provided is a transdermal delivery device configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery device.

The invention provides a dexmedetomidine transdermal patch which comprises a backing layer, a release film and a polymer matrix layer arranged between the backing layer and the release film, the polymer matrix layer comprises dexmedetomidine, povidone and a pressure-sensitive adhesive, based on the total mass of the polymer matrix layer, the dexmedetomidine accounts for 4-10%, the povidone accounts for 5-10%, and the pressure-sensitive adhesive accounts for 5-10%. The povidone accounts for 2-12%, and the pressure-sensitive adhesive accounts for 78-94%; the pressure-sensitive adhesive comprises at least one of polymers containing carboxyl or hydroxyl functionalization.

The present disclosure relates to compositions, formulations, and associated methods for treating neurodegenerative diseases, wherein the compositions include an alpha-1 adrenergic agonist, such as midodrine, and an alpha-2A adrenergic agonist, such as dexmedetomidine. Upon administering to a human subject, the alpha-2A adrenergic agonist crosses the subject's blood-brain barrier thereby acting upon the subject's central nervous system, whereas the alpha-1 adrenergic agonist does not cross the subject's blood-brain barrier. The alpha-1 adrenergic agonist minimizes or eliminates the systemic vascular effects induced by the alpha-2A adrenergic agonist that causes the negative cerebral autoregulatory response, thereby enabling the alpha-2A adrenergic agonist to increase glymphatic flow in the subject's brain.

A preparation method of an external patch for preoperative sedation relates to the field of medical preparations containing organic effective components, and sequentially comprises the steps of preparing a main component pretreatment substance, preparing a matrix solution, preparing an ointment-containing paste and synthesizing the patch, the preparation method of the main component pretreatment substance comprises the following steps: preparing a mixed liquid by taking dexmedetomidine hydrochloride and floperidol as main components, carrying out spray granulation to obtain a composite solid dispersion, crushing the composite solid dispersion into powder, and mixing and stirring the powder with paraffin oil and superfine silica powder. In the patch prepared from dexmedetomidine hydrochloride and floperidol, the effective components can quickly penetrate through the skin mucous membrane, so that the effect of quickly taking effect is achieved, and a good sedative effect is achieved. The dispersion uniformity of main components in the patch is excellent, the RSD is within 2%, and the effect consistency of the patch is guaranteed. According to the dexmedetomidine hydrochloride tablet, the stability of dexmedetomidine hydrochloride is effectively improved, components are prevented from being decomposed in the long-term storage process, other impurities are not generated, and the shelf life is effectively prolonged to 24 months.

The present disclosure relates to methods of using transdermal delivery patches containing dexmedetomidine to treat agitation.

This application relates to the use of dexmedetomidine in the preparation of a drug for protecting the glycocalyx structure of lung tissue, a formulation thereof, and its application, belonging to the field of lung injury technology. This application provides a formulation for protecting the glycocalyx structure of lung tissue, the formulation containing dexmedetomidine, which can protect the glycocalyx structure of lung tissue, thereby reducing lung injury and can be used to treat lung injury.

The present disclosure relates to methods of using transdermal delivery patches containing dexmedetomidine to treat agitation.

The present disclosure relates to methods of using dexmedetomidine for therapeutic purposes wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at least once a day for at least two consecutive days.

The invention discloses application of dexmedetomidine in preparation of a medicine for treating pressure-induced multi-system related diseases of children and adolescents. Aiming at the physiological characteristic that children and adolescents are highly susceptible to pressure due to immature prefrontal cortex, the invention provides that dexmedetomidine can improve the mitochondrial function by regulating the prefrontal cortex GR mitochondrial translocation of the children and adolescents for the first time; therefore, dexmedetomidine is applied to preparation of the medicine for treating the pressure-induced multi-system related diseases of children and adolescents, and a new target is provided for research and development of medicines for depression or other pressure related diseases of children and adolescents which are highly sensitive to pressure. In addition, dexmedetomidine has good safety, and the pain points that existing drugs are insufficient in safety, neglect in growth and development requirements and poor in treatment effect in multi-system related disease people induced by pressure of children and teenagers are solved.

The present disclosure relates to methods of using transdermal delivery patches containing dexmedetomidine to treat agitation.

The application discloses application of Phillygenin combined with dexmedetomidine in improving myocardial ischemia-reperfusion injury and belongs to the technical field of drug development. The drug composition is composed of Phillygenin and dexmedetomidine; the combined use of Phillygenin and dexmedetomidine can reduce myocardial ischemia-reperfusion injury, and compared with the use of Phillygenin or dexmedetomidine alone, the combined use of Phillygenin and dexmedetomidine has a synergistic effect. The combined use of Phillygenin and dexmedetomidine can prevent and treat myocardial ischemia-reperfusion injury and provides a new target for the treatment of myocardial ischemia-reperfusion.

The present application relates to the field of pharmaceutical biotechnology, and specifically relates to a dexmedetomidine-containing transdermal patch. By adding a penetration enhancer, the transdermal rate and transdermal amount are increased, and the onset time is shortened; the patch content is reduced, the residual amount in the skin is lowered, and skin redness / scarring at the administration site caused by drug accumulation in the skin is effectively avoided.

The present disclosure relates to compositions, formulations, and associated methods for treating neurodegenerative diseases, wherein the compositions include an alpha-1 adrenergic agonist, such as midodrine, and an alpha-2A adrenergic agonist, such as dexmedetomidine. Upon administering to a human subject, the alpha-2A adrenergic agonist crosses the subject's blood-brain barrier thereby acting upon the subject's central nervous system, whereas the alpha-1 adrenergic agonist does not cross the subject's blood-brain barrier. The alpha-1 adrenergic agonist minimizes or eliminates the systemic vascular effects induced by the alpha-2A adrenergic agonist that causes the negative cerebral autoregulatory response, thereby enabling the alpha-2A adrenergic agonist to increase glymphatic flow in the subject's brain.

Methods and compositions, e.g., compositions for intravenous administration, comprising dextroamphetamine and / or lisdexamfetamine for use in reversal of dexmedetomidine sedation.

Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. In some embodiments, methods include hydrating the subject, such as by administering a hydration fluid composition to the subject. Methods according to certain embodiments may also include co-administering an opioid to the subject. Also provided is a transdermal delivery device configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery device.

The invention relates to a hyperxic lung injury treatment medicine based on ferroptosis inhibition, a screening method and application, and relates to the technical field of biological medicines. The application has the advantages that ferroptosis is one of key mechanisms of high-oxygen lung injury, a new target spot is provided for clinical prevention and treatment, and in-vivo and in-vitro experiments prove that high oxygen can induce mouse lung microvascular endothelial cells to generate ferroptosis, high oxygen can induce mice to generate acute lung injury, and ferroptosis participates in the process; the ferroptosis related signal path is activated in the hyperxia lung injury; the ferroptosis inhibitor (such as dexmedetomidine, Liproxstatin-1 and deferoxamine) can be used for remarkably relieving the cell injury induced by high oxygen and the pathological change of lung tissues. The target spot and the biomarker provided by the invention can be used for developing a diagnostic kit for evaluating the severity or prognosis of HALI, and the established screening model and method can be used for high-throughput screening of novel anti-HALI compounds to accelerate the research and development process of new drugs.

The application prepares a hyaluronic acid-encapsulated dexmedetomidine microneedle system, which is verified by multidimensional characterization, and the microneedle system has excellent forming property, mechanical property, transdermal and drug release performance, has the characteristics of rapid effect (0.5h cumulative release 43.3%) and long-term delivery (4h cumulative release 86.5%), and has good biocompatibility, and the behavior and electrophysiology experiments confirm that the anti-haze and anti-vomiting effect is remarkable, and because the alpha 2 receptor selectivity is higher, the effect is better than that of clonidine.

Methods for treating stimulant-induced agitation include administering naloxone (NLX) and dexmedetomidine (DEXMED) to a subject in need thereof. Treatment can be directed to a subject having concurrent opioid intoxication and stimulant intoxication. Administration of NLX and DEXMED can include co-administration of NLX and DEXMED or separate administration of NLX and DEXMED to the subject. Administration of DEXMED to the subject can occur at a time when the subject exhibits one or more signs of opioid intoxication and / or at a time when the subject does not exhibit excessive restlessness and movement. Pharmaceutical compositions which include NLX and DEXMED in an amount sufficient to treat concurrent opioid intoxication and stimulant intoxication are also provided.

Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and / or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

The invention discloses a double-drug co-delivery lipidosome and a preparation method and application thereof, and belongs to the technical field of biological medicine, the double-drug co-delivery lipidosome is prepared from the following raw materials: DSPC, DSPE-PEG2K, cholesterol, DSPE-PEG2K-ANG2, DSPE-PEG2K-COG1410 and dexmedetomidine, the mass ratio of the DSPC to the cholesterol to the DSPE-PEG2K to the DSPE-PEG2K-ANG2 to the DSPE-PEG2K-COG1410 to the dexmedetomidine is (28-32): (8-12): (4-6): (2-3): (2-3): (0.4-0.6), the particle size of the lipidosome is 150-200nm, and the The composite nano-drug has the surface potential of 0 to-30 mV, belongs to a composite nano-drug system which has the BBB-crossing capability and regulates and controls microglial cells and neurons, and overcomes the limitation of the existing perioperative neurocognitive dysfunction combined anxiety therapy.

Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition that is formulated to deliver a pain-relieving effective amount of dexmedetomidine to the subject. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. In some embodiments, a method includes hydrating the subject, such as by administering a hydrated fluid composition to the subject. Methods according to certain embodiments may also include co-administering an opioid to the subject. Also provided is a transdermal delivery device configured to deliver dexmedetomidine sufficient for practicing the methods of the invention; and a kit containing the transdermal delivery device.